Regenerative Medical Technology Group INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
Regenerative Medical Technology Group reported a 93.45% revenue increase for Q1 2026, though substantial debt and going concern doubts persist.
OID
Regenerative Medical Technology Group Inc. reported increased revenue but a significantly higher net loss for Q3 2025, driven by rising interest expenses and debt extinguishment losses, while facing substantial doubt about its ability to continue as a going concern.
OID
Regenerative Medical Technology Group Inc. reported significant revenue growth in Q2 2025, but faces severe financial distress with a substantial accumulated deficit and numerous defaulted loans, raising going concern doubts.
OID
Regenerative Medical Technology Group Inc. saw a significant revenue increase in Q1 2025 compared to the previous year, but the company still reported a net loss and faces substantial financial challenges.
OID
Regenerative Medical Technology Group Inc. saw a significant increase in revenue in the third quarter of 2024, but continues to operate with a substantial working capital deficit and faces challenges related to debt and going concern.
OID
10-Q: Meso Numismatics Reports Increased Revenue but Continues to Face Losses and Debt Issues in Q2 2024
Meso Numismatics, Inc. reports a revenue increase for Q2 2024 but continues to struggle with net losses, substantial debt, and going concern uncertainties.
OID
Meso Numismatics, now focused on regenerative medicine through its Global Stem Cells Group, reports a slight increase in revenue but a larger net loss for the quarter ended March 31, 2024.